{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:05:15Z","timestamp":1759579515445},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T00:00:00Z","timestamp":1350345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T00:00:00Z","timestamp":1350345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1038\/leu.2012.295","type":"journal-article","created":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T06:43:08Z","timestamp":1350369788000},"page":"1201-1204","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells"],"prefix":"10.1038","volume":"27","author":[{"given":"D L","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L N","family":"Eadie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V A","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D K","family":"Hiwase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T P","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,16]]},"reference":[{"key":"BFleu2012295_CR1","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","volume":"106","author":"D White","year":"2005","unstructured":"White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106: 2520\u20132526.","journal-title":"Blood"},{"key":"BFleu2012295_CR2","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1200\/JCO.2006.09.9499","volume":"25","author":"D White","year":"2007","unstructured":"White D, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007; 25: 4445\u20134451.","journal-title":"J Clin Oncol"},{"key":"BFleu2012295_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","volume":"108","author":"DL White","year":"2006","unstructured":"White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697\u2013704.","journal-title":"Blood"},{"key":"BFleu2012295_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1177\/0091270009346061","volume":"50","author":"OQ Yin","year":"2010","unstructured":"Yin OQ, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 2010; 50: 960\u2013967.","journal-title":"J Clin Pharmacol"},{"key":"BFleu2012295_CR5","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/jnci\/djh305","volume":"96","author":"F Luciani","year":"2004","unstructured":"Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004; 96: 1702\u20131713.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2012295_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","volume":"364","author":"C Pauli-Magnus","year":"2001","unstructured":"Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF . Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 551\u2013557.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFleu2012295_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.toxlet.2004.12.008","volume":"156","author":"D Balayssac","year":"2005","unstructured":"Balayssac D, Authier N, Cayre A, Coudore F . Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005; 156: 319\u2013329.","journal-title":"Toxicol Lett"},{"key":"BFleu2012295_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.leu.2403257","volume":"18","author":"T Illmer","year":"2004","unstructured":"Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, von Bonin M et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401\u2013408.","journal-title":"Leukemia"},{"key":"BFleu2012295_CR9","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1124\/mol.65.6.1485","volume":"65","author":"C Ozvegy-Laczka","year":"2004","unstructured":"Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004; 65: 1485\u20131495.","journal-title":"Mol Pharmacol"},{"key":"BFleu2012295_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1345\/aph.1E127","volume":"39","author":"G Severino","year":"2005","unstructured":"Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R . Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother 2005; 39: 162\u2013164.","journal-title":"Ann Pharmacother"},{"key":"BFleu2012295_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00280-012-1881-3","volume":"70","author":"OQ Yin","year":"2012","unstructured":"Yin OQ, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 2012; 70: 345\u2013350.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFleu2012295_CR12","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","volume":"28","author":"DL White","year":"2010","unstructured":"White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010; 28: 2761\u20132767.","journal-title":"J Clin Oncol"},{"key":"BFleu2012295_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1046\/j.1365-2036.2000.00788.x","volume":"14","author":"CA Stedman","year":"2000","unstructured":"Stedman CA, Barclay ML . Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963\u2013978.","journal-title":"Aliment Pharmacol Ther"},{"key":"BFleu2012295_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1046\/j.1365-2036.2000.00806.x","volume":"14","author":"WP Geus","year":"2000","unstructured":"Geus WP, Mathot RA, Mulder PG, Lamers CB . Pharmacodynamics and kinetics of omeprazole MUPS 20\u2009mg and pantoprazole 40\u2009mg during repeated oral administration in Helicobacter pylori-negative subjects. Aliment Pharmacol Ther 2000; 14: 1057\u20131064.","journal-title":"Aliment Pharmacol Ther"},{"key":"BFleu2012295_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","volume":"41","author":"Z Desta","year":"2002","unstructured":"Desta Z, Zhao X, Shin JG, Flockhart DA . Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913\u2013958.","journal-title":"Clin Pharmacokinet"},{"key":"BFleu2012295_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1046\/j.1365-2125.1998.t01-1-00702.x","volume":"45","author":"T Andersson","year":"1998","unstructured":"Andersson T, Holmberg J, Rohss K, Walan A . Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998; 45: 369\u2013375.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"BFleu2012295_CR17","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1097\/00042737-199610001-00005","volume":"8","author":"UA Meyer","year":"1996","unstructured":"Meyer UA . Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8 (Suppl 1): S21\u2013S25.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2012295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012295","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:40:09Z","timestamp":1648741209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2012295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,16]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["BFleu2012295"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.295","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,16]]},"assertion":[{"value":"16 October 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DLW and TPH have received research funding from Novartis Oncology. TPH has received Honoraria from Novartis Oncology. The rest of the authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}